Abcombi Biosciences Inc
Biotech · Private
Pneumococcal vaccine using liposomal encapsulation of polysaccharides (LEPS)
- Grants
- $3.7M
- 8 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 2
- 0 granted · 2 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2016201720182019202020212022
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Therapy for drug resistant influenza strains by nucleic acid targeting of respiratory airways | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Therapy for drug resistant influenza strains by nucleic acid targeting of respiratory airways | $349,900 | |
| Federal grant | National Science Foundation · Phase I · SBIR Phase I: Treatment technology for recovery of valuable metals from industrial wastewater | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Therapy for drug resistant influenza strains by nucleic acid targeting of respiratory airways | $49,900 | |
| Federal grant | Department of Health and Human Services · Phase I · Lead Candidate Finalization and a Comprehensive Biological Assessment of a New Class of Pneumococcal Vaccines | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development Of A Liposomal Pneumococcal Vaccine For Clinical Readiness | $715,951 | |
| Federal grant | Department of Health and Human Services · Phase II · Development Of A Liposomal Pneumococcal Vaccine For Clinical Readiness | $940,483 | |
| Federal grant | Department of Health and Human Services · Phase II · Development Of A Liposomal Pneumococcal Vaccine For Clinical Readiness | $856,101 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1410 | GIGAMUNE, INC. | — | — |
| 1411 | Complex Computation, LLC | — | — |
| 1412 | Mirai Bio | — | — |
| 1413 | Abcombi Biosciences Inc | — | — |
| 1414 | DeNovoTherapies LLC | — | — |
| 1415 | Op-T-Mune, Inc | — | — |
| 1416 | COGENTIS THERAPEUTICS INC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Comprehensive Vaccine Design For Commensal Disease Progressionapplication
- Comprehensive Vaccine Design For Commensal Disease Progressionapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.